90 likes | 102 Views
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 pipeline Target constitutes close to 13 molecules. covers products from therapy areas Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Immunology and Musculoskeletal Disorders which include indications Type 2 Diabetes, Alzheimers Disease.<br>https://www.aarkstore.com/pharmaceuticals-healthcare/983130/corticosteroid-11-beta-dehydrogenase-isozyme-1-pipeline-review
E N D
A A R K S T O R E E N T E R P R I S E C O R T I C O S T E R O I D 1 1 B E T A D E H Y D R O G E N A S E I S O Z Y M E 1 P I P E L I N E R 0 E 1 V 8 I E W , H 2 2 W W W . A A R K S T O R E . C O M
O V E R V I E W Corticosteroid 11 Beta Dehydrogenase Isozyme 1 11-beta-hydroxysteroid dehydrogenase type 1 is an NADPH- dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.
C O V E R S P R O D U C T S F R O M T H E R A P Y A R E A S Healthcare market research reports Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Alzheimers Disease, Dementia Associated With Alzheimers Disease, Obesity, Ocular Hypertension, Open-Angle Glaucoma, Cushings Syndrome, Diabetic Complications, Inflammation, Intracranial Hypertension, Metabolic Syndrome, Muscle Atrophy
Report is built using data and information sourced F r o m p r o p r i e t a r y d a t a b a s e s , c o m p a n y / u n i v e r s i t y w e b s i t e s , c l i n i c a l t r i a l r e g i s t r i e s , c o n f e r e n c e s , S E C f i l i n g s , i n v e s t o r p r e s e n t a t i o n s a n d f e a t u r e d p r e s s r e l e a s e s f r o m c o m p a n y / u n i v e r s i t y s i t e s a n d i n d u s t r y - s p e c i f i c t h i r d p a r t y s o u r c e s .
Scope Reasons to buy -Snapshot of the global therapeutic landscape - Gain strategically significant competitor for Corticosteroid 11 Beta Dehydrogenase information, analysis, and insights to Isozyme 1. formulate effective R&D strategies -Reviews Corticosteroid 11 Beta - Identify emerging players with potentially Dehydrogenase Isozyme. strong product portfolio -Dehydrogenase targeted therapeutics under - Identify the use of drugs for target development by companies and research identification and drug repurposing institutes. - Identify potential new clients or partners in - Covers pipeline products based on various the target demographic stages of development. - Develop strategic initiatives by - Features descriptive drug profiles for the understanding the focus areas of leading pipeline products. companies
About Aarkstore A A R K S T O R E M A R K E T R E S E A R C H Aarkstore forms global market research reports from various industry verticals serving businesses worldwide. As market research report resellers, we partner with already established publishers for syndicated data and customized reports. Consequently, market research data by us is up-to-date and reliable for Industry analysis and future market forecasts. Obtain our market research reports and gain information about customer preferences, market requirements, key drivers, and challenges. This will help to make a business align with strategies. The comprehensive overview of the market provided will allow you to make satisfactory decisions, gaining an upper hand in the competitive landscape.
R E L A T E D R E P O R T S Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018 Corticosteroid 11 Beta Dehydrogenase Isozyme-Pipeline Review, H1 2018 11 Beta-Hydroxysteroid Dehydrogenase Type 1(11ßHSD1) Inhibitor -Pipeline Insight, 2018
CONTACT US WEB - www.aarkstore.com PHONE - +91 9987295242 EMAIL - contact@aarkstore.com A A R K S T O R E E N T E R P R I S E
T H A N K Y O U ! W W W . A A R K S T O R E . C O M